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A B S T R A C T
Background
Sore throat is a very common reason for people to present for medical care. Although it remits spontaneously, primary care doctors
commonly prescribe antibiotics for it.
Objectives
To assess the benefits of antibiotics for sore throat.
Search strategy
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) and the Database of Abstracts of Reviews of Effects
(DARE) (The Cochrane Library, Issue 1, 2006), MEDLINE (January 1966 to March 2006) and EMBASE (January 1990 to December
2005).
Selection criteria
Trials of antibiotic against control with either measures of the typical symptoms (throat soreness, headache or fever), or suppurative or
non-suppurative complications of sore throat.
Data collection and analysis
Potential studies were screened independently by two authors for inclusion, with differences in opinion resolved by discussion. Data
were then independently extracted from studies selected by inclusion by two authors. Researchers from three studies were contacted
for additional information.
Main results
There were 27 studies with 2835 cases of sore throat.
1. Non-suppurative complications
There was a trend for antibiotics to protect against acute glomerulonephritis, but there were insufficient cases to be sure. Several studies
found antibiotics reduced acute rheumatic fever by more than two thirds (relative risk (RR) 0.22; 95% CI 0.02 to 2.08).
2. Suppurative complications
Antibiotics reduced the incidence of acute otitis media (RR 0.30; 95% CI 0.15 to 0.58); of acute sinusitis (RR 0.48; 95% CI 0.08 to
2.76); and of quinsy (peritonsillar abscess) compared to those taking placebo (RR 0.15; 95% CI 0.05 to 0.47).
3. Symptoms
Throat soreness and fever were reduced by antibiotics by about one half. The greatest difference was seen at about 3 to 4 days (when the
symptoms of about 50% of untreated patients had settled). By one week about 90% of treated and untreated patients were symptom-
free. The overall number need to treat to prevent one sore throat at day 3 was just under six (95% CI 4.9 to 7.0); at week 1 it was 21
(95% CI 13.2 to 47.9).
4. Subgroup analyses of symptom reduction
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Analysis by: age; blind versus unblinded; or use of antipyretics, found no significant differences.
Analysis of results of throat swabs showed that antibiotics were more effective against symptoms at day 3, RR 0.58 (95% CI 0.48 to
0.71) if the swabs were positive for Streptococcus, compared to RR 0.78 (95% CI 0.63 to 0.97) if negative. Similarly at week 1, RRs
0.29 (95% CI 0.12 to 0.70) for positive, and 0.73 (95% CI 0.50 to 1.07) for negative swabs.
Authors’ conclusions
Antibiotics confer relative benefits in the treatment of sore throat. However, the absolute benefits are modest. Protecting sore throat
sufferers against suppurative and non-suppurative complications in modern Western society can only be achieved by treating many with
antibiotics, most of whom will derive no benefit. In emerging economies (where rates of acute rheumatic fever are high, for example),
the number needed to treat may be much lower for antibiotics to be considered effective. Antibiotics shorten the duration of symptoms
by about sixteen hours overall.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics are of limited use for most people with sore throats
Sore throats are infections caused by bacteria or viruses, affecting mostly children and young adults. People usually recover quickly
(usually after three or four days), although some develop complications. A serious but rare one of these is rheumatic fever, which
affects the heart and joints. Antibiotics reduce bacterial infections. But they can cause diarrhoea, rash and other adverse effects, and
communities build resistance to them. This review of trials found that antibiotics shorten the illness by an average of about one day.
They can reduce the chance of rheumatic fever in communities where this complication is common.
B A C K G R O U N D
Sore throat is a very common reason for people to attend for med-
ical care (ABS 1985). Moreover, four to six times as many peo-
ple suffering sore throat do not seek care (Goslings 1963; Horder
1954). Sore throat is a disease that remits spontaneously, that is,
’cure’ is not dependent on treatment (Del Mar 1992c). Nonethe-
less primary care doctors commonly prescribe antibiotics for sore
throat and other upper respiratory tract infections. There are large
differences in clinical practice between countries (Froom 1990)
and between individual primary care doctors (Howie 1971).
Traditionally, doctors have attempted to decide whether the cause
of the infection is bacterial (when antibiotics might be useful),
especially when caused by the Group A Beta-Haemolytic Strepto-
coccus (which can cause acute rheumatic fever and acute glomeru-
lonephritis). But deciding the etiological agent is difficult (Del
Mar 1992b).
Whether or not to prescribe antibiotics for sore throat is contro-
versial. The issue is important because it is a very common dis-
ease, and differences in prescribing result in large cost differences.
Moreover, increased prescribing increases patient attendance rates
(Howie 1978; Little 1997).
This review was built on an early meta-analysis (Del Mar 1992a).
O B J E C T I V E S
To assess the benefits of antibiotics in the management of acute
sore throat.
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
Randomised or quasi-randomised placebo controlled trials.
Types of participants
Patients presenting for primary care with symptoms of sore throat.
Types of intervention
Antibiotic or placebo control.
Types of outcome measures
At least one of the following: incidence of acute rheumatic fever
within two months; acute glomerulonephritis within one month;
acute otitis media; acute sinusitis; or quinsy, or measures of the
following symptoms: throat soreness, headache or fever.
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S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Cochrane Acute Respiratory Infections Group methods used
in reviews.
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) and the Database of Abstracts of Reviews of Effects
(DARE) (The Cochrane Library, Issue 1, 2006), MEDLINE
(January 1966 to March 2006) and EMBASE (January 1990 to
December 2005).
The MEDLINE and CENTRAL search strategies are shown
below. We combined the MEDLINE search string with the
Cochrane highly sensitive search strategy phases one and two as
published in Appendix 5b of the Cochrane Reviewers’ Handbook
(Higgins 2005). The search string was adapted for EMBASE, as
shown below.
MEDLINE (WebSPIRS)
# 1 explode Pharyngitis/
# 2 pharyngit$.mp.
# 3 explode Nasopharyngitis/
# 4 nasopharyngit$.mp.
# 5 explode Tonsillitis/
# 6 tonsillit$.mp.
# 7 sore throat.mp.
# 8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
# 9 explode Anti-Bacterial Agents/
# 10 antibiot$.mp.
# 11 #9 OR #10
# 12 #8 AND #11
EMBASE (WebSPIRS)
#1 explode ’pharyngitis-’ / all subheadings in
DEM,DER,DRM,DRR
#2 (pharyngit* in ti) or (pharyngit* in ab)
#3 explode ’rhinopharyngitis-’ / all subheadings in
DEM,DER,DRM,DRR
#4 (nasopharyngit* in ti) or (nasopharyngit* in ab)
#5 explode ’tonsillitis-’ / all subheadings in
DEM,DER,DRM,DRR
#6 (tonsillit* in ti) or (tonsillit* in ab)
#7 explode ’sore-throat’ / all subheadings in
DEM,DER,DRM,DRR
#8 (sore throat in ti) or (sore throat in ab)
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
#10 ’antibiotic-agent’ / all subheadings in
DEM,DER,DRM,DRR
#11 (antibiotic* in ti) or (antibiotic* in ab)
#12 #10 or #11
#13 #9 and #12
#14 explode ’randomized-controlled-trial’ / all subheadings
#15 explode ’controlled-study’ / all subheadings
#16 explode ’single-blind-procedure’ / all subheadings
#17 explode ’double-blind-procedure’ / all subheadings
#18 explode ’crossover-procedure’ / all subheadings
#19 explode ’phase-3-clinical-trial’ / all subheadings
#20 (randomi?ed controlled trial in ti) or (randomi?ed controlled
trial in ab)
#21 ((random* or placebo* or double-blind*)in ti) or ((random*
or placebo* or double-blind*)in ab)
#22 (controlled clinical trial* in ti) or (controlled clinical trial* in
ab)
#23 (explode ’randomized-controlled-trial’ / all subheadings)
or (explode ’controlled-study’ / all subheadings) or (explode
’single-blind-procedure’ / all subheadings) or (explode ’double-
blind-procedure’ / all subheadings) or (explode ’crossover-
procedure’ / all subheadings) or (explode ’phase-3-clinical-trial’
/ all subheadings) or ((randomi?ed controlled trial in ti) or
(randomi?ed controlled trial in ab)) or (((random* or placebo*
or double-blind*)in ti) or ((random* or placebo* or double-
blind*)in ab)) or ((controlled clinical trial* in ti) or (controlled
clinical trial* in ab))
#24 (nonhuman in der) not ((human in der)and (nonhuman in
der))
#25 ((explode ’randomized-controlled-trial’ / all subheadings)
or (explode ’controlled-study’ / all subheadings) or (explode
’single-blind-procedure’ / all subheadings) or (explode ’double-
blind-procedure’ / all subheadings) or (explode ’crossover-
procedure’ / all subheadings) or (explode ’phase-3-clinical-trial’
/ all subheadings) or ((randomi?ed controlled trial in ti) or
(randomi?ed controlled trial in ab)) or (((random* or placebo*
or double-blind*)in ti) or ((random* or placebo* or double-
blind*)in ab)) or ((controlled clinical trial* in ti) or (controlled
clinical trial* in ab))) not ((nonhuman in der) not ((human in
der)and (nonhuman in der)))
#26 #13 and #25
References of selected studies and relevant reviews were hand-
checked to find additional studies. No language restrictions were
applied. We determined which studies were trials by examining
the abstracts of identified articles.
M E T H O D S O F T H E R E V I E W
Abstracts of potential studies were screened independently by
two authors, and full articles were retrieved for those that were
trials. The full articles were then examined by two authors and
either selected for inclusion or rejected to the excluded studies list.
Differences in opinion were resolved by discussion.
Data was independently extracted from included studies by two
authors and was based on patient-relevant outcomes: namely
the complications and symptoms listed above. Data extraction
involved reading from tables, graphs and in some cases, by
contacting authors for raw data (Dagnelie 1996; Little 1997; Zwart
2000; Zwart 2003).
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D E S C R I P T I O N O F S T U D I E S
A total of 58 studies were considered for the review. Of these, there
were 27 controlled studies that met inclusion criteria and were
included in the review. The most common reason for exclusion
was lack of appropriate control group (n = 13). Other reasons
for exclusion were: irrelevant or non-patient centred outcomes
(n = six), main complaint other than acute sore throat (n = six),
inappropriate or no randomisation to treatment (n = five), or that
the study reported previously published data already included (n
= one).
The included studies investigated a total of 12,835 cases of sore
throat. The majority of studies were conducted in the 1950s, dur-
ing which time the rates of serious complications (especially acute
rheumatic fever) were much higher than today. Seven recent stud-
ies were included (1996 to 2003), perhaps signalling renewed in-
terest in this topic.
The age of participants ranged from less than one year to older than
50 years. The participants of eight early studies were young male
recruits from the United States air-force. Seven of the remaining
studies recruited children up to 18 years of age only, three recruited
only adults or adolescents aged 15 years or over, and eight studies
had no age restrictions.
All studies recruited patients presenting with symptoms of sore
throat. Seventeen studies did not distinguish between bacterial
and viral aetiology, however eight studies included Group A Beta-
Haemolytic Streptococcus bacterium (GABHS) positive patients
only, whilst two studies excluded patients who were GABHS pos-
itive.
M E T H O D O L O G I C A L Q U A L I T Y
Many of the studies were of poor quality. Only 18 studies were
double blinded: three were single blind. In most early studies sub-
jects were randomised to treatment and control groups by meth-
ods that could potentially introduce bias (for example, air-force
serial number, drawing a card from a deck, hospital bed number)
or not randomised at all. The generalisability of studies can be
questioned. In five studies subjects were excluded if they did not
yield a positive throat-swab culture for Group A Beta-Haemolytic
Streptococcus. In two studies subjects were excluded if they did
yield a positive throat-swab culture for Group A Beta-Haemolytic
Streptococcus (Petersen 1997; Taylor 1977). The use of antipyretic
analgesics was not stated in nine studies, administered routinely
in five studies, and prohibited in four studies. The prohibition
of analgesics might exaggerate any small symptomatic benefit of
antibiotics over control if antipyretic analgesics are usually recom-
mended in normal practice.
R E S U L T S
1. Non-suppurative complications (see Table 01)
Cases of acute glomerulonephritis only occurred in the control
group which suggests protection by antibiotics. However there
were only two cases, and only ten studies reported on acute
glomerulonephritis as an end point. Therefore our estimate of the
protection has a very wide 95% confidence interval (CI), (RR
0.22; 95% CI 0.02 to 2.08) which precludes us from definitively
claiming that antibiotics protect sore throat sufferers from acute
glomerulonephritis.
Several studies found benefit from antibiotics for acute rheumatic
fever which reduced this complication to about one quarter that
in the placebo group (RR 0.27; 95% CI 0.12 to 0.60). Few studies
examined antibiotics other than penicillin. Confining the analysis
to penicillin alone resulted in no difference in estimated protection
(RR 0.27; 95% CI 0.14 to 0.50).
2. Suppurative complications (see Table 01)
Antibiotics reduced the incidence of acute otitis media to about
one third of that in the placebo group, (relative risk (RR) 0.30;
95% CI 0.15 to 0.58) and reduced the incidence of acute sinusitis
to about one half of that in the placebo group (RR 0.48; 95% CI
0.08 to 2.76). Data indicate that the incidence of quinsy was also
reduced in relation to placebo group (RR 0.15; 95% CI 0.05 to
0.47).
3. Symptoms (see Table 01)
At day 3 of illness, antibiotics reduced symptoms of sore throat
(RR 0.68; 95% CI 0.59 to 0.79), fever (RR 0.71; 95% CI 0.45 to
1.10), and headache (RR 0.47; 95% CI 0.38 to 0.58). Day 3 was
the greatest time of benefit because the symptoms of only half the
patients had settled. At one week (six to eight days) the relative
risk of experiencing sore throat was 0.49 (95% CI 0.32 to 0.76),
although 82% of controls were better by this time.
A new trial was included in the 2003 update from Thailand (Lee-
larasamee 2000). It is especially important because it is one of the
few trials from a non-Western industrial country. Unfortunately
we were unable to enter its data into the meta-analysis because of
different ways of collecting the data (in particular no data were
collected mid-way through the illness). Nevertheless, the use of
antibiotics conferred no benefit (nor harms) on symptoms or com-
plications.
4. Subgroup analysis of symptom reduction (see Table 01)
a) Blind versus unblinded studies
There was no significant difference between blinded and un-
blinded studies for symptoms of sore throat at day 3 (RR 0.65;
95% CI 0.54 to 0.78; and RR 0.79; 95% CI 0.60 to 1.05 respec-
tively) nor at one week (RR 0.62; 95% CI 0.38 to 1.03 and RR
0.30; 95% CI 0.08 to 1.15 respectively). Contrary to expectation
the trend was for a greater effect of antibiotics for blind studies at
day 3.
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b) Antipyretics administered versus not administered (see Table
01)
Use of antipyretics offered no significant difference between stud-
ies in which antipyretics were offered and those in which they were
not (RR 0.52; 95% CI 0.33 to 0.81; and RR 0.62; 95% CI 0.55
to 0.70 respectively).
c) Throat swabs positive for Streptococcus, versus negative for
Streptococcus, versus not tested / inseparable combined data
(see the MetaView Table 01)
The probability of still experiencing pain on day 3 is slightly more
than a half (RR 0.58; 95% CI 0.48 to 0.71) for those patients who
had throat swabs positive for Group A Beta-Haemolytic Strepto-
coccus, compared to three quarters (RR 0.78; 95% CI 0.63 to
0.97) for those with negative swabs. There was a similar effect at
one week (RR 0.29; 95% CI 0.12 to 0.70 and RR 0.73; 95% CI
0.50 to 1.07 respectively). That is, the effectiveness of antibiotics
is increased in people with Streptococci growing in the throat.
d) Children versus adults (see Table 01)
There were few studies that included children (less than 13 years
of age): only 61 cases in total for when fever was evaluated at day
3. There was overlap of the RR 95% CI, so that the trend for
children to not experience benefits was not significantly different
to adults who did (RR 1.27; 95% CI 0.76 to 2.13; and RR 0.29;
95% CI 0.06 to 1.51 respectively).
Some of these results are summarised (see Summary of Findings)
D I S C U S S I O N
Natural history
In the placebo groups, after three days, symptoms of sore throat
and fever had disappeared in about 40% and 85% respectively.
Eighty-two percent of patients were symptom free by one week.
This natural history was similar in Streptococcus positive, nega-
tive, and untested patients. About 1.7 per 100 placebo patients
developed rheumatic fever. However, this complication occurred
only in trials reporting before 1961. The background incidence
of acute rheumatic fever has continued to decline in Western so-
cieties since then.
Benefits of treatment
The absolute benefit of antibiotics for the duration of symptoms
was modest. The reduction of illness time is greatest in the middle
of the illness period when the mean absolute reduction is about
one day at around day 3. There are not enough data to make con-
clusions about children. The absolute reduction averaged over the
whole illness can only be estimated from these data. The difference
in the area under the survival curves of sore throat symptoms for
those treated with placebo as opposed to antibiotic is about 16
hours for the first week.
Estimates of the number of people with sore throat who must
be treated to resolve the symptoms of one by day 3 the number
needed-to-treat (NNT) is about 3.7 for those with positive throat
swabs for Streptococcus. It is 6.5 of those with a negative swab, and
14.4 for those in whom no swab has been taken. The last result
is difficult to understand. Intuitively one would expect the NNT
value to lie between both the swab negative and swab positive
results. Perhaps patients with less severe throat infections were
recruited into the three studies in which swabs were not taken.
Antibiotics are effective at reducing the relative complication rate
of people suffering sore throat. However the relative benefit ex-
aggerates the absolute benefit because complication rates are low
and the illness is short lived. Interpretation of these data is aided
by estimating the absolute benefit, which we attempt below.
In these trials, conducted mostly in the 1950s, for every 100 pa-
tients treated with antibiotics rather than placebo, there was one
fewer case of acute rheumatic fever, two fewer cases of acute oti-
tis media, and three fewer cases of quinsy. These figures need to
be adapted to current circumstances and individuals. For example
the complication rate of acute otitis media among those with sore
throats before 1975 was 3%. A NNT of about 50 to prevent one
case of acute otitis media can be estimated from the data. After
1975, this complication rate fell to 0.7%, and applying the odds
of reducing the complication with antibiotics form the data table
yields a NNT of nearly 200 to prevent one case of acute otitis me-
dia. Clinicians will have to exercise judgement in applying these
data to their patients.
In particular in the modern times in the West (where absolute
rates of complications are lower) the NNT will rise above a rate at
which it might be regarded as worthwhile to treat. In developing
countries where the absolute rate may be much higher, the lower
NNT will mean antibiotics are more likely to be effective.
Adverse effects of treatment
We were unable to present the adverse effects of antibiotic
use because of inconsistencies in recording these symptoms. In
other studies these were principally diarrhoea, rashes and thrush
(Glasziou 1997). Consideration of the side effects of antibiotics
would have been useful in further defining their risk-benefits.
Special risk groups
Acute rheumatic fever is common among people living in some
parts of the world (Australian Aborigines living in poor socio-eco-
nomic conditions, for example), and antibiotics may be justified
to reduce the complication of acute rheumatic fever in these set-
tings. In other parts of the world the incidence of acute rheumatic
fever is so low (one estimate is that it took 12 general practitioners’
working lifetimes to encounter one new case of acute rheumatic
fever in Western Scotland in the 1980s (Howie 1985) that the
risks of serious complication arising from using antibiotics for sore
throat might be of the same order as that of acute rheumatic fever.
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Implications for practice
Antibiotics have a beneficial effect on both suppurative and symp-
tom reduction.
The effect on symptoms is small, so that clinicians must judge
with individual cases whether it is clinically justifiable to employ
antibiotics to produce this effect. In other words their use should
be discretionary rather than either prohibited or mandatory. Since
ninety percent of patients are symptom free by one week (whether
or not treated with antibiotics), the absolute benefit of antibiotics
at this time and beyond is vanishingly small.
Acute rheumatic fever is common among people living in some
parts of the world (Australian Aborigines living in poor socio-
economic conditions, for example) and antibiotics may be justified
to reduce the incidence of this complication in these settings. For
other settings where rheumatic fever is rare, there is a balance to
be judged between modest symptom reduction and the hazards of
antimicrobial therapy.
Implications for research
More trials should be conducted in developing countries; in so-
cio-economically deprived sections of developed ones; and also in
children. In modern Western societies better prognostic studies
which can predict which patients may develop suppurative and
non-suppurative complications and may further define which pa-
tients benefit from antibiotics.
Studies which use patient-centred outcome measures compatible
with those presented here would be greatly beneficial, in terms of
easier comparison and analysis of results, and ready inclusion of
the authors work in future updates of this meta-analysis.
Few trials have attempted to measure the severity of symptoms. If
antibiotics reduce the severity as well as the duration of symptoms,
their benefit will have been underestimated in this meta-analysis.
N O T E S
The Acute Respiratory Infections Group would like to thank Dr
Dilruba Nasrin for reading and commenting on this review.
F E E D B A C K
Antibiotics for sore throat
Summary
1. The objectives as they are stated in the abstract include an
assessment of the harms associated with the use of antibiotics in the
management of sore throat, but the objectives as stated in the text
of the review no longer refer to any assessment of harm. Indeed, the
review does not address any adverse effects of antibiotics [which are
not unimportant] and does not provide a reasonable explanation
as to why this is not done other than to state in the discussion that
this was not possible because of inconsistencies in the way these
data were recorded. In the absence of RCT data on harmful effects
the authors might have considered whether usable information
could be provided by other study designs.
2. Reviews on this subject should treat adults and children sepa-
rately, but this review does not attempt to do this.
3. All clinically important outcomes have not been addressed by
the review and others such as resource use, re-attendance and time
off school or work are probably at least as important as those that
were selected. It may have been more helpful to have collected
data on all available outcomes provided that they are free from
detection bias.
4. The question addressed by the review is not sufficiently well
defined to allow the review to be executed systematically. Clear
definitions are not given for the key elements of the question.
Most importantly, clear definitions of what is meant by primary
care and sore throat are not given, leading to confusion around
inclusion and exclusion decisions. Many of the control groups of
the included studies do not involve a placebo but instead simply
compare treatment with antibiotics to no treatment, so that some
excluded studies would be eligible for inclusion, such as Catanzaro
1958 which was excluded because it compared antibiotics with
sulfadiazine.
Apparent errors in inclusion and exclusion decisions have arisen
probably as a result of the general lack of clarity discussed above.
Specifically, the lack of a clear definition of what is meant by pri-
mary care appears to have led to the inclusion of an odd assortment
of studies. For example, a couple of the included trials studied
only people with sore throat who were admitted to hospital (Siegal
1961 and Bennike 1951). In addition, there appears to be an issue
around the definition of a sore throat particularly in relation to
positive or negative Streptococcus throat swabs. Streptococcal sore
throats are a small sub-set of the total population of sore throats
and the failure of the reviewers to address this in the inclusion
criteria means that the results of pragmatic trials of sore throat are
mixed in with those of
streptococcal sore throat.
There is a failure to always faithfully report the detailed results
of the included studies, and there are several numerical errors in
the data abstracted. For example, in Bennike 1951 the baseline
numbers include patients in the “ulcerative tonsillitis” group even
though most outcomes are not reported for this group.
5. The search strategy is restricted to a Medline search, a search of
the Cochrane Library and citation checking. No attempt appears
to have been made to search other databases. The reviewers are not
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explicit about the details of their searching activities nor about how
they used the work of the Cochrane Acute Respiratory Infections
Group.
6. References to the included and excluded studies were incom-
plete. Specifically they were not provided for Dagnelie 1996,
Howie 1997, Little 1997 and Peterson 1997 (included) and Herx
1988, Howie 1970, Marlow 1989, McDonald 1985, Schalen 1993
and Todd 1984 (excluded).
7. Given the nature of the data presented, it is possible that a formal
meta-analysis was inappropriate. A descriptive analysis may have
been more appropriate and more informative.
8. There is considerable uncertainty around the effectiveness of
antibiotics on sore throat on the basis of the existing research
examined by this review and this is not emphasised by the authors.
Particular problems exist around the relevance of the trials to the
present day with regard to the outcomes examined (rheumatic
fever and glomerulonephritis), the poor quality of the majority of
the included trials and the generalisability of the trials with regard
to the study populations (e.g. United States airforce recruits).
Author’s reply
1. This is valid criticism: we need to describe the inadequacies of
the information in the trials (after checking again) in the text.
2. A subgroup analysis on the basis of age is a good idea, and we
will attempt this at the next major review.
3. This is a good idea, and we will attempt this at the next major
review.
4. Certainly the issue of definitions is particularly difficult in this
group of illnesses. One of us has written a paper on these dffi-
culties (Del Mar C. Managing sore throat: a literature review. I.
Making the diagnosis. Med J Aust 1992;156:572-5.). There is a
particular difficulty in the fact that primary care doctors use the
terms ’sore throat’ tonsillitis and pahryngitis in slightly different
ways, including interchangably. Moreover the notion that patients
with postiive swabs for Streptococcus have a differnet illness can
be challenged. Nevertheless a subgroup analysis for this with swab-
positive and swab-negative is a good idea which we will incorpo-
rate with our next review.
Thank for pointing numerical errors out to us, and we will check
on this. Please could you detail other numerical errors for us?
5. We are explicit about our search method. At the time we under-
took the search the Cochrane Acute Respiratory Infections Group
had no meterial to assist us. This will be reviewed at the next major
update.
6. Thank you for drawing our attention to this.
7. As is often the case, there is considerable variation in the popu-
lation groups, treatments, outcomes measures, etc in these trials.
This does not make a synthesis inappropriate, but rather allows us
to examine whether these factors appear to make a difference. We
also felt it important to specifically attempt to calculate the SIZE
of the benefits, as this is what clinicians are interested in, and what
will persuade them to modify their practice. It is then important
to recognise that the size of the effect will vary in different popu-
lations: as we point out, in groups at high risk of rheumatic fever -
such as Australian aboriginals - the prevention of RF is important;
we are also interested in trying to better predict which sub-groups
will experience the most or least symptom relief, and plan to detail
this in the next update.
8. We think we have discussed this in the Review. However we
will reconsider what we have written in the overhaul.
Contributors
Jackie Young (on behalf of an interdepartmental critical appraisal
workshop based in the Department of Public Health and
Epidemiology, The University of Birmingham, UK) Email:
j.m.young.20@bham.ac.uk
Antibiotics for sore throat
Summary
I noticed that trials with no events in either groups are not (cannot)
be part of the pooled estimates. Although I see there is a statistical/
technical problem here it does not seem right. It appears to imply
that no events is no evidence. I wonder whether it is defensible to
add one event in both groups and add the evidence as one would
normally do?
I certify that I have no affiliations with or involvement in any
organisation or entity with a direct financial interest in the subject
matter of my criticisms.
Author’s reply
Many thanks for this. We have gone back and checked with statis-
ticians about your point. The issue seems to be:
1. Whether empty cells are a problem. The concern is that because
one cannot divide anything by zero, this might represent a prob-
lem. We think not, because in no forest plots are there totals with
zero--except for acute glomerulonephritis (there were no cases in
the intervention arms of any trials, and only two in the control
arms).
2. Whether the empty cells represent no evidence or evidence of
no effect. We only recoded a zero where the study declared the
outcome. Thus we assume that “no events” implies no events,
rather than no reporting of events that might have occurred.
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T A B L E S
Characteristics of included studies
Study Bennike 1951
Methods Open study, non-randomised. Subjects allocated to alternate conditions on alternate days
Participants 669 patients aged from less than one year to greater than 50 years of age. Research was divided into three
studies: ordinary tonsillitis, “phlegmonous” tonsillitis and “ulcerative” tonsillitis. Subjects were excluded if
they had a complication of tonsillitis on admission or if they had previous antibiotic treatment for the present
sore throat
Interventions Age adjusted intramuscular penicillin twice daily for six days or no treatment as a control condition
Outcomes Incidence of rheumatic fever, otitis media, quinsy, sinusitis and symptoms of sore throat and headache
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Notes No antipyretics were administered to the control group. The use of antipyretics to subjects in the treatment
group was unstated
Allocation concealment C – Inadequate
Study Brink 1951
Methods Open study, randomised by airforce serial number
Participants 395 young adult males recruited into United States Airforce
Interventions Intramuscular penicillin over four days, chlortetracycline for three days, or no treatment as control group
Outcomes Incidence of rheumatic fever, otitis media, and symptoms of sore throat, fever and headache
Notes No antipyretics were administered
Allocation concealment C – Inadequate
Study Brumfitt 1957
Methods Open study, randomised by bed number
Participants 121 young adult men, aged eighteen to twenty one years, recruited into United States Airforce. Patients were
excluded from study if their temperature was below 99.3 degrees F, if they had sore throat for more than 72
hours prior to presentation, or if they had some other generalised illness
Interventions Intramuscular penicillin twice daily for four days or no treatment as a control condition
Outcomes Incidence of rheumatic fever and symptoms of sore throat and fever
Notes Aspirin gargles were given 6 hourly. Whether subjects were permitted to swallow the aspirin was not docu-
mented
Allocation concealment C – Inadequate
Study Catanzaro 1954
Methods Single blind, patients were unaware of treatment type, placebo controlled trial. The outcome of treatment
was not determined blind. Patients were randomly allocated by airforce serial number
Participants 640 young adult males recruited into United States Airforce. Missing data were not explained
Data from patients who produced a Group A Beta Haemolytic Streptococcus negative throat swab were
excluded. Subjects were excluded if they presented with a suppurative complication at the time of admission
Interventions Intramuscular penicillin administered for five days, sulphonamide administered for five days, or no treatment
as a control condition
Outcomes Incidence of rheumatic fever
Notes Antipyretic use was not documented
Allocation concealment C – Inadequate
Study Chamovitz 1954
Methods Single blind placebo study. Patients did not know treatment type they were receiving. The outcome of
treatment was not determined blind. Subjects were randomised by airforce serial number
Participants 366 young adult males recruited into United States Airforce. Patients were excluded if they had previously
developed rheumatic fever, had previous penicillin reaction, or if they had a suppurative complication at the
time of admission
Interventions Intramuscular penicillin
Outcomes Incidence of rheumatic fever, otitis media, and sinusitis
Notes Antipyretic use was not documented
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Allocation concealment C – Inadequate
Study Chapple 1956
Methods Double blind placebo trial, randomised by random bottle dispensing
Participants 308 subjects aged greater than two years old. Data from 283 subjects included in analyses
Interventions Age adjusted oral penicillin, sulphadimidine, or barium sulphate (placebo) administered for five days
Outcomes Incidence of rheumatic fever, otitis media, and symptom of sore throat
Notes All groups received controlled doses of antipyretics twice daily for three days
Data from only 200 subjects presenting with sore throat on day 1 included in sore throat analysis
Allocation concealment A – Adequate
Study Dagnelie 1996
Methods Randomised double-blind placebo controlled trial of penicillin V on the course and bacteriological response
in patients with sore throat in general practice
Participants 239 patients aged 4 to 60, presenting with sore-throat to 37 general practices in the Netherlands, who were
clinically suspected of GABHS
Interventions Treatment with either penicillin V, or placebo
Outcomes Resolution of sore throat, fever, and return to daily activities (assessed by doctor, and by diary for 7 days)
Notes * Need raw data to make this study comparable to the meta-analysis, however data are available for sore
throat on day 3 and quinsy
Allocation concealment A – Adequate
Study De Meyere 1992
Methods Double blind placebo trial. Method of randomisation to treatment groups was not documented
Participants 173 patients aged five to fifty years, from the Gent region of Belgium
Data was obtained from 173 subjects on days one and three
Data was obtained form 131 subjects on days two, four, five, six and seven
Subjects excluded if they: produced a Group A Beta Haemolytic Streptococcus negative throat swab, had a
sore throat for greater than five days, had a previous history of acute rheumatic fever, had an allergy to beta-
lactam antibiotics, had received any antibiotics within the past fourteen days, were in any high risk situation
as determined by the physician
Interventions Oral penicillin or oral placebo three times a day
Outcomes Symptom of sore throat
All data obtained, except from days one and three, were self report from a diary
Notes Antipyretics were used as required by participants. Use of antipyretics and other symptom relieving methods
was documented in a diary
Allocation concealment A – Adequate
Study Denny 1950
Methods Single blind study. The outcome was determined blind on follow up by physicians who did not know what
treatment type each subject had received. Subject were randomised to groups by airforce serial number
Participants 1602 young adult males recruited into United States Airforce
Interventions Intramuscular penicillin for four days or no treatment as a control group
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Outcomes Incidence of rheumatic fever only
Notes Antipyretic use was not stated
Allocation concealment C – Inadequate
Study Denny 1953
Methods Single blind trial. Oral placebo used. Patients were randomly allocated to treatment groups by drawing a
card from a deck. Outcome determined blind by physicians who did not know treatment type
Participants 103 young adult males recruited in the United States Airforce. Patients were excluded if they had no exudate
on their tonsils or larynx, if they had a leukocyte count of less than 10,000; or if they had experienced
symptoms of sore throat for more than 31 hours
Interventions Intramuscular penicillin daily for five days, oral aureomycin or oral terramycin administered every six hours
for 3 days or oral lactose placebo for three days as a control condition
Outcomes Incidence of acute rheumatic fever, otitis media, quinsy, sinusitis, and symptoms of sore throat and headache
Notes No antipyretics were administered
Allocation concealment B – Unclear
Study El-Daher 1991
Methods Double-blinded, randomised controlled trial
Participants 229 children with positive culture for GABHS
Interventions Early treatment with oral penicillin for 10 days versus oral placebo for 2 days followed by oral penicillin for
8 days
Outcomes Symptoms of sore throat and headache on day 3
Notes Examination of patients was done on day 3 before administering penicillin to placebo group
Allocation concealment A – Adequate
Study Howe 1997
Methods 22 GPs in one region of the UK recruited
Participants 154 patients aged 16 to 60 years presenting to their GP with sore throat, and for whom the GP would
normally prescribe an antibiotic
Interventions Therapy with either penicillin V (250 mg four times a day), cefixime (200 mg daily), or placebo
Outcomes Resolution of a composite “symptom score” with time; eradication of GABHS. A diary was kept of symptom
resolution over 7 days
Notes Unusual randomisation scheme (done in blocks of 6)
*Symptom results were bundled into a composite “symptom score”. The raw data on sore throat, cough and
fever resolution has been requested from the authors
Allocation concealment A – Adequate
Study Krober 1985
Methods Double blind placebo trial. Subjects were randomised by table of random numbers
Participants Forty-four children presenting to a paediatric clinic. Twenty-six of these subjects yielded group A beta
haemolytic streptococcus positive throat swabs.
Subjects were excluded if: the duration of symptoms was greater than 72 hours; they had received oral
antibiotics within the past 72 hours or intramuscular antibiotics within the past 30 days; they had history
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of penicillin allergy; they had a rash suggestive of scarlet fever; they had a concurrent infection that required
antibiotics other than penicillin; or if they had sever illness requiring immediate penicillin treatment.
Subjects who produced Group A Beta Haemolytic Streptococcus negative throat swabs were excluded from
the study
Interventions Oral penicillin or similar looking and tasting oral placebo for the control condition, three times a day for
three days
Outcomes Symptom of fever
Notes Antipyretic use was not documented
Allocation concealment A – Adequate
Study Landsman 1951
Methods Double blind placebo. Randomised by random numbering of bottles
Participants 95 patients who presented to general practice complaining of sore throat
Interventions Oral sulphonamide or similar looking and tasting oral placebo, for the control condition
Outcomes Incidence of sinusitis or quinsy or symptoms of sore throat or fever
Notes Antipyretic use was not documented
Allocation concealment A – Adequate
Study Leelarasamee 2000
Methods Double-blind randomised placebo controlled trial
Participants 1217 patients aged over 5 years presenting to four community -based medical centres with complaints of
fever or sore throat of less than ten days duration
Interventions Patients were randomised to receive either Amoxycillin or placebo for seven days
Outcomes Duration of sore throat and fever. incidence of complications and adverse reactions
Notes Antipyretics were given if deemed necessary by physicians
Allocation concealment A – Adequate
Study Little 1997
Methods Unblinded randomised trial
Participants 716 patients aged 4 years and over, presenting to their GP with a sore throat, with an abnormal physical
finding localised to the throat (e.g. inflamed tonsils or pharynx, etc)
Interventions Patients were randomised to three groups. Patients in the first group were given an antibiotic for 10 days;
those in the second group were given no prescription; and in the third group were given an offer of antibiotic
prescription if the symptoms were not starting to settle after 3 days
Outcomes Main outcomes - duration of symptoms, satisfaction and compliance with and perceived efficacy of antibiotics,
time off school or work. Patients given a daily diary in which to record symptoms and temperature. Patients
who did not return diaries were followed up over the phone
Notes Patients randomised, but neither patients or doctors blinded to the therapy
Allocation concealment C – Inadequate
Study MacDonald 1951
Methods Outcome determined blind. Randomised by airforce serial number
Participants 82 young adult males recruited into the United States Airforce
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41 in treatment group; 41 in control group
Interventions Oral sulphatriad or identical oral lactose placebo, administered to the control condition, taken every four
hours
Outcomes Symptom of sore throat
Notes Antipyretics were administered to 1 subject in the treatment group and 2 subjects in the control group
Allocation concealment C – Inadequate
Study Middleton 1988
Methods Multi-center, double-blind, randomised, placebo-controlled
Participants One hundred and seventy-eight patients aged 4 to 29 years with streptococcal pharyngitis. Patients had
symptom duration of less than 4 days. Results reported for 57 patients with severe illness only
Interventions Eight individual doses of penicillin or unmedicated placebo
Outcomes Symptoms of sore throat and fever
Notes Phone report after 48 hours used to measure outcome at day 3
Allocation concealment D – Not used
Study Nelson 1984
Methods Subject randomised to conditions by hospital number allocation. An oral placebo was used to single blind
patients, however outcome was not determined blind
Participants 51 children aged 5 to 11 years. Sixteen subjects were excluded because they did not produce Group A Beta
Haemolytic Streptococcus positive throat swabs, leaving 35 subjects. Children with history of penicillin
hypersensitivity were also excluded
Interventions Intramuscular penicillin or oral syrup placebo as a control group
Outcomes Symptoms of sore throat and fever
Notes No antipyretics were administered
Allocation concealment C – Inadequate
Study Petersen 1997
Methods Randomised placebo-controlled trial of patients’ culture negative to Group A Streptococcus
Participants One hundred and eighty-six adults (aged 18 to 50) presenting to an ambulatory setting, whose chief complaint
was sore throat, and whose GAS culture was subsequently found to be negative
Interventions Treatment of either erythromycin (333 mg, 3 times daily), or placebo
Outcomes Main outcomes - time to improvement in sore throat, cough, activity level, and sense of well being. Patients
completed a daily questionnaire on the progress of outcome measures. Follow up visits were arranged 2 to 3
weeks after enrolment for repeat cultures, collect diaries and assess compliance
Notes It is not clear how many patients kept diaries for the sore throat data in each group. Authors excluded GAS
positive patients, (15 out of 212 initially randomised). Authors are being contacted for raw data
Allocation concealment A – Adequate
Study Pichichero 1987
Methods Double blind placebo trial, randomised by a table of random numbers
Participants One hundred and fourteen Group A Beta Haemolytic Streptococcus positive children aged 4 to 18 years.
Children were excluded from the study if: a throat swab was negative for Group A Beta Haemolytic Strep-
tococcus; were allergic to penicillin; had received penicillin in past 7 days; had another acute illness within
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seven days, had a Group A Beta Haemolytic Streptococcus positive swab in past month, or had another
concurrent infection that required antibiotics
Interventions Oral penicillin for forty eight hours or an identical looking and tasting oral placebo used for the control
condition
Outcomes Incidence of otitis media, quinsy, or sinusitis
Notes Antipyretics administered 4 hourly
Allocation concealment A – Adequate
Study Siegel 1961
Methods Open study, randomised by bed chart number
Participants One thousand, two hundred and thirteen patients aged three to sixteen years. Suppurative complications
occurring in subjects in the control condition were treated with sulphonamides. Subjects were excluded if
they had a complication on admission
Interventions Intramuscular penicillin or no treatment for the controls
Outcomes Incidence of rheumatic fever
Notes Antipyretic use was not documented
Allocation concealment C – Inadequate
Study Taylor 1977
Methods Double blind placebo trial. The method of randomisation to groups was not documented
Participants One hundred and twenty-two children aged two to ten years. Children with positive Streptococcus throat
swabs were excluded
Nine children were excluded during trial because of pre-existing suppurative complications
Interventions Oral amoxycillin, oral cotrimoxazole, or an oral placebo was administered by parents three times a day for
five days
Outcomes Incidence of otitis media and sinusitis and symptoms of sore throat and fever
Notes Antipyretic use was not documented
Allocation concealment A – Adequate
Study Wannamaker 1951
Methods Single blind study. The outcome of intervention was determined blind by physicians who did not know
treatment type participants were receiving Randomised to groups by airforce serial number
Participants One thousand, nine hundred and seventy-four young adult males recruited into the United States Airforce
Interventions Intramuscular penicillin over one to three days or no treatment for the control condition
Outcomes Incidence of rheumatic fever
Notes Antipyretic use was not documented
Allocation concealment C – Inadequate
Study Whitfield 1981
Methods Double blind placebo trial. Randomised by predetermined random order
Participants Subjects were patients who presented to the general practitioner with sore throat, aged greater than 10 years.
Seven hundred and forty-five patients were commenced in study. Only 528 returned questionnaires. Subjects
were excluded if the general practitioner thought the subject would demonstrate poor compliance; if they
had previous reaction to penicillin; or a previous episode of rheumatic fever or acute nephritis
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Interventions Oral penicillin four times a day for five days or identical looking and tasting oral lactose placebo four times
a day for five days
Outcomes Symptom of fever
Notes Antipyretic use was not documented
Allocation concealment A – Adequate
Study Zwart 2000
Methods Double blind, randomised placebo controlled trial
Participants Five hundred and sixty-one patients aged 15 to 60 years presenting with sore throat of less than seven days
duration
Interventions Penicillin V for seven days, penicillin V for 3 days followed by 4 days of placebo or placebo or 7 days
Outcomes Resolution of symptoms and recurrence of sore throat
Notes Author was contacted for data that could be used in the meta-analysis
Allocation concealment A – Adequate
Study Zwart 2003
Methods Double blind, randomised placebo controlled trial
Participants One hundred and fifty-six children aged 4 to 15 years presenting with sore throat of less than 7 days duration
with at least 2 of 4 Centor criteria
Interventions Penicillin V for seven days, penicillin V for 3 days followed by 4 days of placebo or placebo or 7 days
Outcomes Duration of symptoms of sore throat, occurrence of streptococcal sequelae
Notes Author was contacted for data that could be used in the meta-analysis
Allocation concealment A – Adequate
F = fareheit
Characteristics of excluded studies
Study Reason for exclusion
Barwitz 1999 Patients were randomised to two GPs for subsequent treatment with different management protocols
Bass 1986 Study used a Likert scale to measure severity and duration of symptoms. No raw scores are available for entry into
meta-analysis
Bishop 1952 Non-randomised allocation to treatment groups. (Quote) “Where an exceptionally severe case fell in the control
group and it was felt unjustifiable to withhold specific treatment, the case was transferred to one of the other
groups and the next case was placed in the control group.” This bias was not quantified
Catanzaro 1958 Study compared sulphonamides with other antibiotics. No control condition was used
Cruickshank 1960 Study is another report of the data previously published by Brunfitt, 1957
Dowell 2001 Cough was the main complaint for patients, not sore throat
Gerber 1985 Study compared two different regimens of penicillin. No placebo control group was used
Gerber 1989 Assessed two regimes of penicillin. No control group used
Ginsburg 1980 Study compared penicillin V with cefadroxil. No placebo control group was used
Guthrie 1988 Study did not use control condition
Haverkorn 1971 Subjects not treated with antibiotics given antipyretics. Subjects receiving antibiotics received no antipyretics. No
control condition
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Herz 1988 No patient centred outcomes, except return visits for URIs.
Poor randomisation - out of a series of 202, the first and last 50 were assigned to antibiotics, with the middle 102
assigned to control
Howie 1970 Illness was “cold or flu-like illness”, not acute pharyngitis (exclusively). Soreness of throat not an outcome measure
Jensen 1991 Patients were not randomly allocated to treatment groups and were not blinded to treatment
Marlow 1989 Patient population highly selected (non-pregnant, negative rapid strep. test, negative throat culture, no other
infection present, not allergic to erythromycin, aged older than 12), and patient-centred outcomes not compatible
with those in this meta-analysis
Massell 1951 Study examined effect of penicillin on hemolytic streptococcic infections in rheumatic patients only, without
randomisation to control condition. Infections that were not treated with penicillin for ’various reasons’ were
treated as controls. These reasons were not given
McDonald 1985 No data suitable for this meta-analysis were described although symptoms were recorded. The author was ap-
proached for these data, but no reply was received
Merenstein 1974 No data on suppurative or non-suppurative complications.
No data on day three for soreness of throat, fever, or headache
Morris 1956 Study observed effect of Sulfadiazine on prevention of rheumatic fever only. No control condition was used
Nasonova 1999 Study in a controlled clinical trial without randomisation of subjects
Pandraud 2002 Investigation of effect of fusafune on chronic conditions of follicular pharyngitis. Not relevant for this review
Randolph 1985 No data on suppurative or non-suppurative complications.
No data on day three or seven for soreness of throat, fever, or headache
Schalen 1985 Primary complaint hoarseness, not sore throat. No patient centred outcomes apart from hoarseness
Schalen 1993 Patients presented for laryngitis and hoarseness, not pharyngitis
Schwartz 1981 Study compared seven versus ten days of treatment with penicillin. No control group was used
Shevrygin 2000 Study was a clinical trial without a control condition
Shvartzman 1993 Study compared efficacy of amoxycillin against penicillin, no control condition was used
Stillerman 1986 Study compared penicillin with cephalosporins. No control group was used
Stromberg 1988 No placebo control group was used. Study compared different antibiotic regimens
Todd 1984 Primary complaint not sore throat - purulent nasopharyngitis instead
Valkenburg 1971 Study did not involve any control measures. Data only given for subjects not treated with antibiotics
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3621 (15) 0.66 0.72 0.68-0.76 19 A
Sore Throat:
Day 7
2974 (13) 0.18 0.65 0.55-0.76 6.4 A
Rheumatic
Fever
10,101 (16) 0.017 0.29 0.18-0.44 1.2 A Based largely
on risk in
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5147 (10) 0.001 0.22 0.07-1.32 0.1 B Sparse data
Quinsy 2433 (8) 0.023 0.14 0.05-0.39 2.0 A
Otitis Media 3760 (11) 0.02 0.28 0.15-0.52 1.4 A
A N A L Y S E S





participants Statistical method Effect size
01 Incidence of acute rheumatic
fever within two months.
Rheumatic fever defined by
clinical diagnosis
16 10101 Peto Odds Ratio 95% CI 0.30 [0.20, 0.45]
02 Incidence of acute rheumatic
fever within two months.
Penicillin versus control
14 8175 Peto Odds Ratio 95% CI 0.27 [0.18, 0.41]
03 Incidence of acute rheumatic
fever within two months: early
(pre-1975) versus late studies
(post-1975)
16 10101 Peto Odds Ratio 95% CI 0.30 [0.20, 0.45]
04 Incidence of otitis media within
14 days. Otitis media defined
by clinical diagnosis
11 3760 Peto Odds Ratio 95% CI 0.23 [0.12, 0.44]
05 Incidence of otitis media within
14 days: early (pre-1975) versus
late studies (post-1975)
11 3760 Peto Odds Ratio 95% CI 0.23 [0.12, 0.44]
06 Incidence of sinusitis within
14 days. Sinusitis defined by
clinical diagnosis
8 2387 Peto Odds Ratio 95% CI 0.46 [0.10, 2.05]
07 Incidence of quinsy within two
months. Quinsy defined by
clinical diagnosis
8 2433 Peto Odds Ratio 95% CI 0.16 [0.07, 0.35]
08 Incidence of acute
glomerulonephritis
within one month. Acute
glomerulonephritis defined by
clinical diagnosis
10 5147 Peto Odds Ratio 95% CI 0.07 [0.00, 1.32]
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participants Statistical method Effect size
01 Symptom of sore throat on day
three
15 3621 Peto Odds Ratio 95% CI 0.44 [0.38, 0.50]
02 Symptom of sore throat on day
three: blind versus unblinded
studies
15 3621 Peto Odds Ratio 95% CI 0.44 [0.38, 0.50]
03 Symptom of sore throat on day
three: antipyretics versus no
antipyretics
5 1137 Peto Odds Ratio 95% CI 0.31 [0.24, 0.40]
04 Symptom of sore throat on day
three: Streptococcus positive
throat swab, negative swab,
untested/ inseparable
20 3600 Peto Odds Ratio 95% CI 0.42 [0.36, 0.48]
05 Symptom of sore throat at one
week (six to eight days)
13 2974 Peto Odds Ratio 95% CI 0.55 [0.44, 0.69]
06 Symptom of sore throat at one
week (six to eight days): blind
versus unblinded studies
13 2944 Peto Odds Ratio 95% CI 0.59 [0.47, 0.74]
07 Symptom of sore throat at
one week (six to eight days):
GABHS positive throat swab,
GABHS negative swab. Untes
15 2524 Peto Odds Ratio 95% CI 0.49 [0.37, 0.65]





participants Statistical method Effect size
03 Symptom of fever on day three 7 1334 Peto Odds Ratio 95% CI 0.62 [0.46, 0.85]
04 Symptom of fever on day
three: blinded versus unblinded
studies
7 1334 Peto Odds Ratio 95% CI 0.62 [0.46, 0.85]
05 Symptom of fever on day three:
children compared with adults
4 657 Peto Odds Ratio 95% CI 0.44 [0.29, 0.66]
06 Symptom of fever at one week
(six to eight days)
3 777 Peto Odds Ratio 95% CI Not estimable





participants Statistical method Effect size
03 Symptom of headache on day
three
3 911 Peto Odds Ratio 95% CI 0.33 [0.25, 0.45]
04 Symptom of headache on day
three: blinded versus unblinded
studies
3 911 Peto Odds Ratio 95% CI 0.33 [0.25, 0.45]
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Analysis 01.01. Comparison 01 Antibiotics versus control for the treatment of sore throat: incidence of
complications, Outcome 01 Incidence of acute rheumatic fever within two months. Rheumatic fever defined
by clinical diagnosis
Review: Antibiotics for sore throat
Comparison: 01 Antibiotics versus control for the treatment of sore throat: incidence of complications
Outcome: 01 Incidence of acute rheumatic fever within two months. Rheumatic fever defined by clinical diagnosis
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
x Bennike 1951 0/238 0/268 0.0 Not estimable
Brink 1951 2/277 5/198 6.9 0.29 [ 0.06, 1.31 ]
x Brumfitt 1957 0/62 0/59 0.0 Not estimable
Catanzaro 1954 26/650 12/220 28.0 0.71 [ 0.33, 1.49 ]
Chamovitz 1954 0/257 2/109 1.7 0.03 [ 0.00, 0.72 ]
x Chapple 1956 0/186 0/97 0.0 Not estimable
x Dagnelie 1996 0/121 0/118 0.0 Not estimable
x De Meyere 1992 0/87 0/94 0.0 Not estimable
Denny 1950 2/798 17/804 19.2 0.20 [ 0.08, 0.50 ]
Denny 1953 2/157 1/50 2.2 0.60 [ 0.04, 8.59 ]
x Leelarasamee 2000 0/369 0/386 0.0 Not estimable
x Little 1997 0/454 0/216 0.0 Not estimable
x Pichichero 1987 0/59 0/58 0.0 Not estimable
Siegel 1961 0/605 2/608 2.0 0.14 [ 0.01, 2.17 ]
Wannamaker 1951 5/978 35/996 40.0 0.22 [ 0.12, 0.41 ]
x Zwart 2000 0/358 0/164 0.0 Not estimable
Total (95% CI) 5656 4445 100.0 0.30 [ 0.20, 0.45 ]
Total events: 37 (Treatment), 74 (Control)
Test for heterogeneity chi-square=9.20 df=6 p=0.16 I² =34.8%
Test for overall effect z=5.94 p<0.00001
0.1 0.2 0.5 1 2 5 10
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Analysis 01.02. Comparison 01 Antibiotics versus control for the treatment of sore throat: incidence of
complications, Outcome 02 Incidence of acute rheumatic fever within two months. Penicillin versus control
Review: Antibiotics for sore throat
Comparison: 01 Antibiotics versus control for the treatment of sore throat: incidence of complications
Outcome: 02 Incidence of acute rheumatic fever within two months. Penicillin versus control
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
x Bennike 1951 0/238 0/268 0.0 Not estimable
Brink 1951 2/197 5/198 7.5 0.42 [ 0.09, 1.87 ]
x Brumfitt 1957 0/62 0/59 0.0 Not estimable
Catanzaro 1954 12/420 12/220 22.8 0.49 [ 0.21, 1.15 ]
Chamovitz 1954 0/257 2/109 1.8 0.03 [ 0.00, 0.72 ]
x Chapple 1956 0/99 0/97 0.0 Not estimable
x Dagnelie 1996 0/121 0/118 0.0 Not estimable
x De Meyere 1992 0/87 0/94 0.0 Not estimable
Denny 1950 2/798 17/804 20.6 0.20 [ 0.08, 0.50 ]
Denny 1953 1/53 1/50 2.2 0.94 [ 0.06, 15.30 ]
x Pichichero 1987 0/59 0/58 0.0 Not estimable
Siegel 1961 0/605 2/608 2.2 0.14 [ 0.01, 2.17 ]
Wannamaker 1951 5/978 35/996 42.9 0.22 [ 0.12, 0.41 ]
x Zwart 2000 0/358 0/164 0.0 Not estimable
Total (95% CI) 4332 3843 100.0 0.27 [ 0.18, 0.41 ]
Total events: 22 (Treatment), 74 (Control)
Test for heterogeneity chi-square=5.71 df=6 p=0.46 I² =0.0%
Test for overall effect z=6.27 p<0.00001
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 01.03. Comparison 01 Antibiotics versus control for the treatment of sore throat: incidence of
complications, Outcome 03 Incidence of acute rheumatic fever within two months: early (pre-1975) versus
late studies (post-1975)
Review: Antibiotics for sore throat
Comparison: 01 Antibiotics versus control for the treatment of sore throat: incidence of complications
Outcome: 03 Incidence of acute rheumatic fever within two months: early (pre-1975) versus late studies (post-1975)
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 Incidence of acute rheumatic fever within 2 months: early (pre-1975) studies
x Bennike 1951 0/238 0/268 0.0 Not estimable
Brink 1951 2/277 5/198 6.9 0.29 [ 0.06, 1.31 ]
x Brumfitt 1957 0/62 0/59 0.0 Not estimable
Catanzaro 1954 26/650 12/220 28.0 0.71 [ 0.33, 1.49 ]
Chamovitz 1954 0/257 2/109 1.7 0.03 [ 0.00, 0.72 ]
x Chapple 1956 0/186 0/97 0.0 Not estimable
Denny 1950 2/798 17/804 19.2 0.20 [ 0.08, 0.50 ]
Denny 1953 2/157 1/50 2.2 0.60 [ 0.04, 8.59 ]
Siegel 1961 0/605 2/608 2.0 0.14 [ 0.01, 2.17 ]
Wannamaker 1951 5/978 35/996 40.0 0.22 [ 0.12, 0.41 ]
Subtotal (95% CI) 4208 3409 100.0 0.30 [ 0.20, 0.45 ]
Total events: 37 (Treatment), 74 (Control)
Test for heterogeneity chi-square=9.20 df=6 p=0.16 I² =34.8%
Test for overall effect z=5.94 p<0.00001
02 Incidence of actue rheumatic fever within 2 months: late (post-1975) studies
x Dagnelie 1996 0/121 0/118 0.0 Not estimable
x De Meyere 1992 0/87 0/94 0.0 Not estimable
x Leelarasamee 2000 0/369 0/386 0.0 Not estimable
x Little 1997 0/454 0/216 0.0 Not estimable
x Pichichero 1987 0/59 0/58 0.0 Not estimable
x Zwart 2000 0/358 0/164 0.0 Not estimable
Subtotal (95% CI) 1448 1036 0.0 Not estimable
Total events: 0 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 5656 4445 100.0 0.30 [ 0.20, 0.45 ]
Total events: 37 (Treatment), 74 (Control)
Test for heterogeneity chi-square=9.20 df=6 p=0.16 I² =34.8%
Test for overall effect z=5.94 p<0.00001
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Analysis 01.04. Comparison 01 Antibiotics versus control for the treatment of sore throat: incidence of
complications, Outcome 04 Incidence of otitis media within 14 days. Otitis media defined by clinical diagnosis
Review: Antibiotics for sore throat
Comparison: 01 Antibiotics versus control for the treatment of sore throat: incidence of complications
Outcome: 04 Incidence of otitis media within 14 days. Otitis media defined by clinical diagnosis
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Bennike 1951 0/238 2/268 5.6 0.15 [ 0.01, 2.43 ]
Brink 1951 5/277 13/198 47.9 0.27 [ 0.10, 0.71 ]
Chamovitz 1954 0/257 1/109 2.4 0.03 [ 0.00, 2.53 ]
Chapple 1956 5/186 5/97 24.7 0.49 [ 0.13, 1.83 ]
x Dagnelie 1996 0/121 0/118 0.0 Not estimable
x De Meyere 1992 0/87 0/94 0.0 Not estimable
Denny 1953 0/157 2/50 4.1 0.02 [ 0.00, 0.40 ]
Little 1997 0/454 1/216 2.5 0.04 [ 0.00, 2.98 ]
Pichichero 1987 1/59 0/55 2.8 6.90 [ 0.14, 348.82 ]
Taylor 1977 0/131 4/66 10.0 0.05 [ 0.01, 0.39 ]
x Zwart 2000 0/358 0/164 0.0 Not estimable
Total (95% CI) 2325 1435 100.0 0.23 [ 0.12, 0.44 ]
Total events: 11 (Treatment), 28 (Control)
Test for heterogeneity chi-square=10.42 df=7 p=0.17 I² =32.8%
Test for overall effect z=4.41 p=0.00001
0.1 0.2 0.5 1 2 5 10
27Antibiotics for sore throat (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Analysis 01.05. Comparison 01 Antibiotics versus control for the treatment of sore throat: incidence of
complications, Outcome 05 Incidence of otitis media within 14 days: early (pre-1975) versus late studies
(post-1975)
Review: Antibiotics for sore throat
Comparison: 01 Antibiotics versus control for the treatment of sore throat: incidence of complications
Outcome: 05 Incidence of otitis media within 14 days: early (pre-1975) versus late studies (post-1975)
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 Incidence of otitis media within 14 days: early (pre-1975) studies
Bennike 1951 0/238 2/268 5.6 0.15 [ 0.01, 2.43 ]
Brink 1951 5/277 13/198 47.9 0.27 [ 0.10, 0.71 ]
Chamovitz 1954 0/257 1/109 2.4 0.03 [ 0.00, 2.53 ]
Chapple 1956 5/186 5/97 24.7 0.49 [ 0.13, 1.83 ]
Denny 1953 0/157 2/50 4.1 0.02 [ 0.00, 0.40 ]
Subtotal (95% CI) 1115 722 84.7 0.25 [ 0.12, 0.52 ]
Total events: 10 (Treatment), 23 (Control)
Test for heterogeneity chi-square=4.74 df=4 p=0.32 I² =15.6%
Test for overall effect z=3.74 p=0.0002
02 Incidence of otitis media within 14 days: late (post-1975) studies
x Dagnelie 1996 0/121 0/118 0.0 Not estimable
x De Meyere 1992 0/87 0/94 0.0 Not estimable
Little 1997 0/454 1/216 2.5 0.04 [ 0.00, 2.98 ]
Pichichero 1987 1/59 0/55 2.8 6.90 [ 0.14, 348.82 ]
Taylor 1977 0/131 4/66 10.0 0.05 [ 0.01, 0.39 ]
x Zwart 2000 0/358 0/164 0.0 Not estimable
Subtotal (95% CI) 1210 713 15.3 0.12 [ 0.02, 0.65 ]
Total events: 1 (Treatment), 5 (Control)
Test for heterogeneity chi-square=5.04 df=2 p=0.08 I² =60.3%
Test for overall effect z=2.46 p=0.01
Total (95% CI) 2325 1435 100.0 0.23 [ 0.12, 0.44 ]
Total events: 11 (Treatment), 28 (Control)
Test for heterogeneity chi-square=10.42 df=7 p=0.17 I² =32.8%
Test for overall effect z=4.41 p=0.00001
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Analysis 01.06. Comparison 01 Antibiotics versus control for the treatment of sore throat: incidence of
complications, Outcome 06 Incidence of sinusitis within 14 days. Sinusitis defined by clinical diagnosis
Review: Antibiotics for sore throat
Comparison: 01 Antibiotics versus control for the treatment of sore throat: incidence of complications
Outcome: 06 Incidence of sinusitis within 14 days. Sinusitis defined by clinical diagnosis
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Chamovitz 1954 1/257 3/109 48.2 0.11 [ 0.01, 0.97 ]
x Dagnelie 1996 0/121 0/118 0.0 Not estimable
x De Meyere 1992 0/87 0/84 0.0 Not estimable
Denny 1953 0/157 1/50 10.6 0.02 [ 0.00, 1.55 ]
Landsman 1951 2/52 0/43 28.5 6.34 [ 0.39, 104.15 ]
Little 1997 1/454 0/216 12.7 4.37 [ 0.07, 289.80 ]
x Pichichero 1987 0/59 0/58 0.0 Not estimable
x Zwart 2000 0/358 0/164 0.0 Not estimable
Total (95% CI) 1545 842 100.0 0.46 [ 0.10, 2.05 ]
Total events: 4 (Treatment), 4 (Control)
Test for heterogeneity chi-square=8.19 df=3 p=0.04 I² =63.4%
Test for overall effect z=1.02 p=0.3
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Analysis 01.07. Comparison 01 Antibiotics versus control for the treatment of sore throat: incidence of
complications, Outcome 07 Incidence of quinsy within two months. Quinsy defined by clinical diagnosis
Review: Antibiotics for sore throat
Comparison: 01 Antibiotics versus control for the treatment of sore throat: incidence of complications
Outcome: 07 Incidence of quinsy within two months. Quinsy defined by clinical diagnosis
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Bennike 1951 1/238 15/268 65.1 0.19 [ 0.07, 0.50 ]
Dagnelie 1996 0/121 2/118 8.4 0.13 [ 0.01, 2.10 ]
x De Meyere 1992 0/87 0/94 0.0 Not estimable
Howe 1997 1/69 0/34 3.7 4.45 [ 0.07, 287.35 ]
Landsman 1951 0/52 2/43 8.3 0.11 [ 0.01, 1.76 ]
Little 1997 0/454 1/216 3.7 0.04 [ 0.00, 2.98 ]
x Pichichero 1987 0/59 0/58 0.0 Not estimable
Zwart 2000 0/358 3/164 10.8 0.04 [ 0.00, 0.47 ]
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(. . . Continued)
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Total (95% CI) 1438 995 100.0 0.16 [ 0.07, 0.35 ]
Total events: 2 (Treatment), 23 (Control)
Test for heterogeneity chi-square=4.17 df=5 p=0.53 I² =0.0%
Test for overall effect z=4.53 p<0.00001
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Analysis 01.08. Comparison 01 Antibiotics versus control for the treatment of sore throat: incidence of
complications, Outcome 08 Incidence of acute glomerulonephritis within one month. Acute
glomerulonephritis defined by clinical diagnosis
Review: Antibiotics for sore throat
Comparison: 01 Antibiotics versus control for the treatment of sore throat: incidence of complications
Outcome: 08 Incidence of acute glomerulonephritis within one month. Acute glomerulonephritis defined by clinical diagnosis
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
x Bennike 1951 0/238 0/268 0.0 Not estimable
x Brink 1951 0/277 0/198 0.0 Not estimable
x Brumfitt 1957 0/62 0/59 0.0 Not estimable
Chamovitz 1954 0/257 1/109 45.5 0.03 [ 0.00, 2.53 ]
x Chapple 1956 0/186 0/97 0.0 Not estimable
x Dagnelie 1996 0/121 0/118 0.0 Not estimable
x Leelarasamee 2000 0/369 0/386 0.0 Not estimable
x Little 1997 0/454 0/216 0.0 Not estimable
Siegel 1961 0/605 1/605 54.5 0.14 [ 0.00, 6.82 ]
x Zwart 2000 0/358 0/164 0.0 Not estimable
Total (95% CI) 2927 2220 100.0 0.07 [ 0.00, 1.32 ]
Total events: 0 (Treatment), 2 (Control)
Test for heterogeneity chi-square=0.21 df=1 p=0.65 I² =0.0%
Test for overall effect z=1.77 p=0.08
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Analysis 02.01. Comparison 02 Antibiotics versus control for the treatment of sore throats: symptom of sore
throat, Outcome 01 Symptom of sore throat on day three
Review: Antibiotics for sore throat
Comparison: 02 Antibiotics versus control for the treatment of sore throats: symptom of sore throat
Outcome: 01 Symptom of sore throat on day three
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Brink 1951 119/277 129/198 14.7 0.41 [ 0.29, 0.59 ]
Brumfitt 1957 21/42 26/40 2.6 0.55 [ 0.23, 1.30 ]
Chapple 1956 40/135 37/65 5.3 0.32 [ 0.17, 0.58 ]
Dagnelie 1996 36/117 57/117 7.2 0.47 [ 0.28, 0.80 ]
De Meyere 1992 18/82 59/91 5.5 0.18 [ 0.10, 0.32 ]
Denny 1953 89/157 48/50 4.3 0.17 [ 0.09, 0.34 ]
El-Daher 1991 42/111 106/118 6.7 0.10 [ 0.06, 0.18 ]
Landsman 1951 6/52 7/43 1.4 0.67 [ 0.21, 2.16 ]
Little 1997 135/215 122/187 11.8 0.90 [ 0.60, 1.35 ]
MacDonald 1951 18/41 27/41 2.6 0.42 [ 0.18, 0.99 ]
Middleton 1988 2/34 5/23 0.8 0.24 [ 0.05, 1.16 ]
Petersen 1997 60/89 74/90 4.3 0.46 [ 0.23, 0.90 ]
Whitfield 1981 129/256 165/272 16.6 0.66 [ 0.47, 0.93 ]
Zwart 2000 215/358 131/164 12.8 0.41 [ 0.28, 0.61 ]
Zwart 2003 79/100 38/56 3.4 1.80 [ 0.85, 3.83 ]
Total (95% CI) 2066 1555 100.0 0.44 [ 0.38, 0.50 ]
Total events: 1009 (Treatment), 1031 (Control)
Test for heterogeneity chi-square=76.91 df=14 p=<0.0001 I² =81.8%
Test for overall effect z=11.63 p<0.00001
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Analysis 02.02. Comparison 02 Antibiotics versus control for the treatment of sore throats: symptom of sore
throat, Outcome 02 Symptom of sore throat on day three: blind versus unblinded studies
Review: Antibiotics for sore throat
Comparison: 02 Antibiotics versus control for the treatment of sore throats: symptom of sore throat
Outcome: 02 Symptom of sore throat on day three: blind versus unblinded studies
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 Symptom of sore throat on day 3: blinded studies.
Chapple 1956 40/135 37/65 5.3 0.32 [ 0.17, 0.58 ]
Dagnelie 1996 36/117 57/117 7.2 0.47 [ 0.28, 0.80 ]
De Meyere 1992 18/82 59/91 5.5 0.18 [ 0.10, 0.32 ]
Denny 1953 89/157 48/50 4.3 0.17 [ 0.09, 0.34 ]
El-Daher 1991 42/111 106/118 6.7 0.10 [ 0.06, 0.18 ]
Landsman 1951 6/52 7/43 1.4 0.67 [ 0.21, 2.16 ]
MacDonald 1951 18/41 27/41 2.6 0.42 [ 0.18, 0.99 ]
Middleton 1988 2/34 5/23 0.8 0.24 [ 0.05, 1.16 ]
Petersen 1997 60/89 74/90 4.3 0.46 [ 0.23, 0.90 ]
Whitfield 1981 129/256 165/272 16.6 0.66 [ 0.47, 0.93 ]
Zwart 2000 215/358 131/164 12.8 0.41 [ 0.28, 0.61 ]
Zwart 2003 79/100 38/56 3.4 1.80 [ 0.85, 3.83 ]
Subtotal (95% CI) 1532 1130 71.0 0.39 [ 0.33, 0.46 ]
Total events: 734 (Treatment), 754 (Control)
Test for heterogeneity chi-square=62.56 df=11 p=<0.0001 I² =82.4%
Test for overall effect z=11.17 p<0.00001
02 Symptom of sore throat on day 3: unblinded studies.
Brink 1951 119/277 129/198 14.7 0.41 [ 0.29, 0.59 ]
Brumfitt 1957 21/42 26/40 2.6 0.55 [ 0.23, 1.30 ]
Little 1997 135/215 122/187 11.8 0.90 [ 0.60, 1.35 ]
Subtotal (95% CI) 534 425 29.0 0.58 [ 0.45, 0.75 ]
Total events: 275 (Treatment), 277 (Control)
Test for heterogeneity chi-square=7.86 df=2 p=0.02 I² =74.6%
Test for overall effect z=4.12 p=0.00004
Total (95% CI) 2066 1555 100.0 0.44 [ 0.38, 0.50 ]
Total events: 1009 (Treatment), 1031 (Control)
Test for heterogeneity chi-square=76.91 df=14 p=<0.0001 I² =81.8%
Test for overall effect z=11.63 p<0.00001
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Analysis 02.03. Comparison 02 Antibiotics versus control for the treatment of sore throats: symptom of sore
throat, Outcome 03 Symptom of sore throat on day three: antipyretics versus no antipyretics
Review: Antibiotics for sore throat
Comparison: 02 Antibiotics versus control for the treatment of sore throats: symptom of sore throat
Outcome: 03 Symptom of sore throat on day three: antipyretics versus no antipyretics
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 Symptom of sore throat on day 3: antipyretics administered.
Brumfitt 1957 21/42 26/40 8.0 0.55 [ 0.23, 1.30 ]
Chapple 1956 40/135 37/65 16.4 0.32 [ 0.17, 0.58 ]
De Meyere 1992 18/82 59/91 16.8 0.18 [ 0.10, 0.32 ]
Subtotal (95% CI) 259 196 41.2 0.28 [ 0.19, 0.41 ]
Total events: 79 (Treatment), 122 (Control)
Test for heterogeneity chi-square=4.63 df=2 p=0.10 I² =56.8%
Test for overall effect z=6.55 p<0.00001
03 Symptom of sore throat on day 3: no antipyretics administered.
Brink 1951 119/277 129/198 45.4 0.41 [ 0.29, 0.59 ]
Denny 1953 89/157 48/50 13.4 0.17 [ 0.09, 0.34 ]
Subtotal (95% CI) 434 248 58.8 0.34 [ 0.25, 0.47 ]
Total events: 208 (Treatment), 177 (Control)
Test for heterogeneity chi-square=4.88 df=1 p=0.03 I² =79.5%
Test for overall effect z=6.63 p<0.00001
Total (95% CI) 693 444 100.0 0.31 [ 0.24, 0.40 ]
Total events: 287 (Treatment), 299 (Control)
Test for heterogeneity chi-square=10.09 df=4 p=0.04 I² =60.4%
Test for overall effect z=9.29 p<0.00001
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Analysis 02.04. Comparison 02 Antibiotics versus control for the treatment of sore throats: symptom of sore
throat, Outcome 04 Symptom of sore throat on day three: Streptococcus positive throat swab, negative swab,
untested/ inseparable
Review: Antibiotics for sore throat
Comparison: 02 Antibiotics versus control for the treatment of sore throats: symptom of sore throat
Outcome: 04 Symptom of sore throat on day three: Streptococcus positive throat swab, negative swab, untested/ inseparable
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 Symptom of sore throat on day 3: Group A Beta Haemolytic Streptococcus positive throat swab
Brink 1951 119/277 129/198 14.8 0.41 [ 0.29, 0.59 ]
Brumfitt 1957 21/42 26/40 2.6 0.55 [ 0.23, 1.30 ]
Chapple 1956 13/68 22/41 2.9 0.21 [ 0.09, 0.48 ]
Dagnelie 1996 13/55 36/55 3.5 0.19 [ 0.09, 0.39 ]
De Meyere 1992 18/82 59/91 5.5 0.18 [ 0.10, 0.32 ]
Denny 1953 89/157 48/50 4.4 0.17 [ 0.09, 0.34 ]
El-Daher 1991 42/111 106/118 6.7 0.10 [ 0.06, 0.18 ]
MacDonald 1951 13/26 17/24 1.6 0.43 [ 0.14, 1.31 ]
Middleton 1988 2/24 5/23 0.8 0.36 [ 0.07, 1.74 ]
Zwart 2000 102/178 68/83 6.6 0.34 [ 0.20, 0.59 ]
Zwart 2003 39/53 28/43 2.6 1.49 [ 0.62, 3.56 ]
Subtotal (95% CI) 1073 766 51.9 0.28 [ 0.23, 0.34 ]
Total events: 471 (Treatment), 544 (Control)
Test for heterogeneity chi-square=40.42 df=10 p=<0.0001 I² =75.3%
Test for overall effect z=12.74 p<0.00001
02 Symptom of sore throat on day 3: Group A Beta Haemolytic Streptococcus negative throat swab
Chapple 1956 13/67 16/26 2.1 0.14 [ 0.05, 0.38 ]
Dagnelie 1996 31/60 29/51 3.5 0.81 [ 0.39, 1.71 ]
MacDonald 1951 5/15 10/17 1.0 0.37 [ 0.09, 1.46 ]
Petersen 1997 60/89 74/90 4.3 0.46 [ 0.23, 0.90 ]
Zwart 2000 113/180 63/81 6.3 0.51 [ 0.29, 0.89 ]
Zwart 2003 40/47 10/13 0.7 1.78 [ 0.35, 9.15 ]
Subtotal (95% CI) 458 278 18.1 0.48 [ 0.35, 0.67 ]
Total events: 262 (Treatment), 202 (Control)
Test for heterogeneity chi-square=10.52 df=5 p=0.06 I² =52.5%
Test for overall effect z=4.30 p=0.00002
03 Symptom of sore throat on day 3: Untested for GABHS culture or combined inseperable data
Landsman 1951 6/52 7/43 1.4 0.67 [ 0.21, 2.16 ]
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(. . . Continued)
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Little 1997 135/215 122/187 11.8 0.90 [ 0.60, 1.35 ]
Whitfield 1981 129/256 165/272 16.7 0.66 [ 0.47, 0.93 ]
Subtotal (95% CI) 523 502 30.0 0.75 [ 0.58, 0.96 ]
Total events: 270 (Treatment), 294 (Control)
Test for heterogeneity chi-square=1.33 df=2 p=0.51 I² =0.0%
Test for overall effect z=2.24 p=0.03
Total (95% CI) 2054 1546 100.0 0.42 [ 0.36, 0.48 ]
Total events: 1003 (Treatment), 1040 (Control)
Test for heterogeneity chi-square=88.42 df=19 p=<0.0001 I² =78.5%
Test for overall effect z=12.24 p<0.00001
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Analysis 02.05. Comparison 02 Antibiotics versus control for the treatment of sore throats: symptom of sore
throat, Outcome 05 Symptom of sore throat at one week (six to eight days)
Review: Antibiotics for sore throat
Comparison: 02 Antibiotics versus control for the treatment of sore throats: symptom of sore throat
Outcome: 05 Symptom of sore throat at one week (six to eight days)
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Bennike 1951 0/100 7/99 2.2 0.13 [ 0.03, 0.57 ]
Brink 1951 4/277 15/198 5.8 0.20 [ 0.08, 0.51 ]
Brumfitt 1957 0/42 2/40 0.6 0.13 [ 0.01, 2.04 ]
Dagnelie 1996 3/51 15/51 4.9 0.20 [ 0.07, 0.55 ]
De Meyere 1992 3/61 10/70 3.8 0.35 [ 0.11, 1.11 ]
Denny 1953 6/157 16/50 4.7 0.05 [ 0.02, 0.15 ]
x Landsman 1951 0/52 0/43 0.0 Not estimable
Little 1997 66/388 35/184 23.8 0.87 [ 0.55, 1.38 ]
MacDonald 1951 0/41 1/41 0.3 0.14 [ 0.00, 6.82 ]
Petersen 1997 21/89 32/90 12.3 0.57 [ 0.30, 1.07 ]
Taylor 1977 6/129 3/59 2.4 0.91 [ 0.22, 3.84 ]
Zwart 2000 117/352 63/154 32.2 0.72 [ 0.48, 1.06 ]
Zwart 2003 20/100 7/56 6.8 1.68 [ 0.71, 3.99 ]
Total (95% CI) 1839 1135 100.0 0.55 [ 0.44, 0.69 ]
Total events: 246 (Treatment), 206 (Control)
Test for heterogeneity chi-square=46.59 df=11 p=<0.0001 I² =76.4%
Test for overall effect z=5.20 p<0.00001
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Analysis 02.06. Comparison 02 Antibiotics versus control for the treatment of sore throats: symptom of sore
throat, Outcome 06 Symptom of sore throat at one week (six to eight days): blind versus unblinded studies
Review: Antibiotics for sore throat
Comparison: 02 Antibiotics versus control for the treatment of sore throats: symptom of sore throat
Outcome: 06 Symptom of sore throat at one week (six to eight days): blind versus unblinded studies
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 Symptom of sore throat at 1 week (6-8 days): blinded studies
Dagnelie 1996 4/47 3/35 2.1 0.99 [ 0.21, 4.71 ]
De Meyere 1992 3/51 10/70 3.8 0.42 [ 0.13, 1.34 ]
Denny 1953 6/157 16/50 4.9 0.05 [ 0.02, 0.15 ]
x Landsman 1951 0/52 0/43 0.0 Not estimable
MacDonald 1951 0/41 1/41 0.3 0.14 [ 0.00, 6.82 ]
Petersen 1997 21/89 32/90 12.7 0.57 [ 0.30, 1.07 ]
Taylor 1977 6/129 3/59 2.5 0.91 [ 0.22, 3.84 ]
Zwart 2000 117/352 63/154 33.2 0.72 [ 0.48, 1.06 ]
Zwart 2003 20/100 7/56 7.0 1.68 [ 0.71, 3.99 ]
Subtotal (95% CI) 1018 598 66.5 0.61 [ 0.46, 0.80 ]
Total events: 177 (Treatment), 135 (Control)
Test for heterogeneity chi-square=29.52 df=7 p=0.0001 I² =76.3%
Test for overall effect z=3.52 p=0.0004
02 Symptom of sore throat at 1 week (6-8 days): unblinded studies
Bennike 1951 0/100 7/99 2.3 0.13 [ 0.03, 0.57 ]
Brink 1951 4/277 15/198 6.0 0.20 [ 0.08, 0.51 ]
Brumfitt 1957 0/42 2/40 0.7 0.13 [ 0.01, 2.04 ]
Little 1997 66/388 35/184 24.5 0.87 [ 0.55, 1.38 ]
Subtotal (95% CI) 807 521 33.5 0.57 [ 0.38, 0.84 ]
Total events: 70 (Treatment), 59 (Control)
Test for heterogeneity chi-square=13.00 df=3 p=0.005 I² =76.9%
Test for overall effect z=2.84 p=0.005
Total (95% CI) 1825 1119 100.0 0.59 [ 0.47, 0.74 ]
Total events: 247 (Treatment), 194 (Control)
Test for heterogeneity chi-square=42.59 df=11 p=<0.0001 I² =74.2%
Test for overall effect z=4.51 p<0.00001
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Analysis 02.07. Comparison 02 Antibiotics versus control for the treatment of sore throats: symptom of sore
throat, Outcome 07 Symptom of sore throat at one week (six to eight days): GABHS positive throat swab,
GABHS negative swab. Untes
Review: Antibiotics for sore throat
Comparison: 02 Antibiotics versus control for the treatment of sore throats: symptom of sore throat
Outcome: 07 Symptom of sore throat at one week (six to eight days): GABHS positive throat swab, GABHS negative swab. Untes
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 Symptom of sore throat at 1 week (6-8days): Group A Beta Heamolytic Streptococcus positive throat swab
Brink 1951 4/277 15/198 8.7 0.20 [ 0.08, 0.51 ]
Brumfitt 1957 0/42 2/40 1.0 0.13 [ 0.01, 2.04 ]
Dagnelie 1996 1/34 10/42 4.6 0.19 [ 0.05, 0.68 ]
De Meyere 1992 3/61 10/70 5.7 0.35 [ 0.11, 1.11 ]
Denny 1953 6/157 16/50 7.1 0.05 [ 0.02, 0.15 ]
MacDonald 1951 0/26 1/24 0.5 0.12 [ 0.00, 6.29 ]
Zwart 2003 8/53 3/43 4.7 2.21 [ 0.63, 7.75 ]
Subtotal (95% CI) 650 467 32.3 0.23 [ 0.14, 0.37 ]
Total events: 22 (Treatment), 57 (Control)
Test for heterogeneity chi-square=21.38 df=6 p=0.002 I² =71.9%
Test for overall effect z=5.99 p<0.00001
02 Symptom of sore throat at 1 week (6-8days): Group A Beta Heamolytic Streptococcus negative throat swab
Dagnelie 1996 3/35 4/47 3.1 1.01 [ 0.21, 4.78 ]
x MacDonald 1951 0/15 0/17 0.0 Not estimable
Petersen 1997 21/89 32/90 18.3 0.57 [ 0.30, 1.07 ]
Taylor 1977 6/129 3/59 3.6 0.91 [ 0.22, 3.84 ]
Zwart 2003 12/47 4/13 4.0 0.77 [ 0.19, 3.05 ]
Subtotal (95% CI) 315 226 29.0 0.67 [ 0.40, 1.11 ]
Total events: 42 (Treatment), 43 (Control)
Test for heterogeneity chi-square=0.75 df=3 p=0.86 I² =0.0%
Test for overall effect z=1.57 p=0.1
03 Symptom of sore throat at 1 week (6-8days): Group A Beta Heamolytic Streptococcus untested
Bennike 1951 0/100 7/99 3.3 0.13 [ 0.03, 0.57 ]
x Landsman 1951 0/52 0/43 0.0 Not estimable
Little 1997 66/388 35/184 35.5 0.87 [ 0.55, 1.38 ]
Subtotal (95% CI) 540 326 38.8 0.74 [ 0.48, 1.15 ]
Total events: 66 (Treatment), 42 (Control)
Test for heterogeneity chi-square=5.81 df=1 p=0.02 I² =82.8%
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(. . . Continued)
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Test for overall effect z=1.35 p=0.2
Total (95% CI) 1505 1019 100.0 0.49 [ 0.37, 0.65 ]
Total events: 130 (Treatment), 142 (Control)
Test for heterogeneity chi-square=42.21 df=12 p=<0.0001 I² =71.6%
Test for overall effect z=5.09 p<0.00001
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Analysis 03.03. Comparison 03 Antibiotics versus control for the treatment of sore throat: symptom of fever,
Outcome 03 Symptom of fever on day three
Review: Antibiotics for sore throat
Comparison: 03 Antibiotics versus control for the treatment of sore throat: symptom of fever
Outcome: 03 Symptom of fever on day three
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Brink 1951 34/277 40/198 38.4 0.55 [ 0.33, 0.91 ]
Brumfitt 1957 6/62 19/59 12.6 0.26 [ 0.11, 0.62 ]
x Krober 1985 0/15 0/11 0.0 Not estimable
Landsman 1951 1/52 3/43 2.4 0.29 [ 0.04, 2.14 ]
Middleton 1988 1/33 0/21 0.6 5.14 [ 0.09, 286.24 ]
Nelson 1984 12/17 10/18 5.3 1.87 [ 0.48, 7.23 ]
Whitfield 1981 33/256 42/272 40.6 0.81 [ 0.50, 1.32 ]
Total (95% CI) 712 622 100.0 0.62 [ 0.46, 0.85 ]
Total events: 87 (Treatment), 114 (Control)
Test for heterogeneity chi-square=9.49 df=5 p=0.09 I² =47.3%
Test for overall effect z=2.99 p=0.003
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Analysis 03.04. Comparison 03 Antibiotics versus control for the treatment of sore throat: symptom of fever,
Outcome 04 Symptom of fever on day three: blinded versus unblinded studies
Review: Antibiotics for sore throat
Comparison: 03 Antibiotics versus control for the treatment of sore throat: symptom of fever
Outcome: 04 Symptom of fever on day three: blinded versus unblinded studies
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 Symptom of fever on day 3: blinded studies.
x Krober 1985 0/15 0/11 0.0 Not estimable
Landsman 1951 1/52 3/43 2.4 0.29 [ 0.04, 2.14 ]
Middleton 1988 1/33 0/21 0.6 5.14 [ 0.09, 286.24 ]
Whitfield 1981 33/256 42/272 40.6 0.81 [ 0.50, 1.32 ]
Subtotal (95% CI) 356 347 43.7 0.79 [ 0.49, 1.26 ]
Total events: 35 (Treatment), 45 (Control)
Test for heterogeneity chi-square=1.81 df=2 p=0.40 I² =0.0%
Test for overall effect z=1.00 p=0.3
02 Symptom of fever on day 3: unblinded studies.
Brink 1951 34/277 40/198 38.4 0.55 [ 0.33, 0.91 ]
Brumfitt 1957 6/62 19/59 12.6 0.26 [ 0.11, 0.62 ]
Nelson 1984 12/17 10/18 5.3 1.87 [ 0.48, 7.23 ]
Subtotal (95% CI) 356 275 56.3 0.52 [ 0.34, 0.79 ]
Total events: 52 (Treatment), 69 (Control)
Test for heterogeneity chi-square=5.99 df=2 p=0.05 I² =66.6%
Test for overall effect z=3.10 p=0.002
Total (95% CI) 712 622 100.0 0.62 [ 0.46, 0.85 ]
Total events: 87 (Treatment), 114 (Control)
Test for heterogeneity chi-square=9.49 df=5 p=0.09 I² =47.3%
Test for overall effect z=2.99 p=0.003
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Analysis 03.05. Comparison 03 Antibiotics versus control for the treatment of sore throat: symptom of fever,
Outcome 05 Symptom of fever on day three: children compared with adults
Review: Antibiotics for sore throat
Comparison: 03 Antibiotics versus control for the treatment of sore throat: symptom of fever
Outcome: 05 Symptom of fever on day three: children compared with adults
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 Symptom of fever on day 3: children
x Krober 1985 0/15 0/11 0.0 Not estimable
Nelson 1984 12/17 10/18 9.3 1.87 [ 0.48, 7.23 ]
Subtotal (95% CI) 32 29 9.3 1.87 [ 0.48, 7.23 ]
Total events: 12 (Treatment), 10 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.91 p=0.4
02 Symptom of fever on day 3: adults
Brink 1951 34/277 40/198 67.3 0.55 [ 0.33, 0.91 ]
Catanzaro 1954 3/62 24/59 23.4 0.13 [ 0.05, 0.30 ]
Subtotal (95% CI) 339 257 90.7 0.38 [ 0.24, 0.58 ]
Total events: 37 (Treatment), 64 (Control)
Test for heterogeneity chi-square=8.23 df=1 p=0.004 I² =87.9%
Test for overall effect z=4.41 p=0.00001
Total (95% CI) 371 286 100.0 0.44 [ 0.29, 0.66 ]
Total events: 49 (Treatment), 74 (Control)
Test for heterogeneity chi-square=13.12 df=2 p=0.001 I² =84.8%
Test for overall effect z=3.93 p=0.00009
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Analysis 03.06. Comparison 03 Antibiotics versus control for the treatment of sore throat: symptom of fever,
Outcome 06 Symptom of fever at one week (six to eight days)
Review: Antibiotics for sore throat
Comparison: 03 Antibiotics versus control for the treatment of sore throat: symptom of fever
Outcome: 06 Symptom of fever at one week (six to eight days)
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
x Brink 1951 0/277 0/198 0.0 Not estimable
x Denny 1950 0/157 0/50 0.0 Not estimable
x Landsman 1951 0/52 0/43 0.0 Not estimable
Total (95% CI) 486 291 0.0 Not estimable
Total events: 0 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 04.03. Comparison 04 Antibiotics versus control for the treatment of sore throat: symptom of
headache, Outcome 03 Symptom of headache on day three
Review: Antibiotics for sore throat
Comparison: 04 Antibiotics versus control for the treatment of sore throat: symptom of headache
Outcome: 03 Symptom of headache on day three
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Brink 1951 61/277 80/198 57.2 0.42 [ 0.28, 0.62 ]
Denny 1953 54/157 30/50 21.7 0.35 [ 0.18, 0.66 ]
El-Daher 1991 7/118 37/111 21.1 0.17 [ 0.09, 0.33 ]
Total (95% CI) 552 359 100.0 0.33 [ 0.25, 0.45 ]
Total events: 122 (Treatment), 147 (Control)
Test for heterogeneity chi-square=5.05 df=2 p=0.08 I² =60.4%
Test for overall effect z=7.17 p<0.00001
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Analysis 04.04. Comparison 04 Antibiotics versus control for the treatment of sore throat: symptom of
headache, Outcome 04 Symptom of headache on day three: blinded versus unblinded studies
Review: Antibiotics for sore throat
Comparison: 04 Antibiotics versus control for the treatment of sore throat: symptom of headache
Outcome: 04 Symptom of headache on day three: blinded versus unblinded studies
Study Treatment Control Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 Symptom headache on day three: blinded studies
Denny 1953 54/157 30/50 21.7 0.35 [ 0.18, 0.66 ]
El-Daher 1991 7/118 37/111 21.1 0.17 [ 0.09, 0.33 ]
Subtotal (95% CI) 275 161 42.8 0.25 [ 0.16, 0.39 ]
Total events: 61 (Treatment), 67 (Control)
Test for heterogeneity chi-square=2.22 df=1 p=0.14 I² =55.0%
Test for overall effect z=5.97 p<0.00001
03 Symptom of headache on day three: unblinded studies
Brink 1951 61/277 80/198 57.2 0.42 [ 0.28, 0.62 ]
Subtotal (95% CI) 277 198 57.2 0.42 [ 0.28, 0.62 ]
Total events: 61 (Treatment), 80 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=4.32 p=0.00002
Total (95% CI) 552 359 100.0 0.33 [ 0.25, 0.45 ]
Total events: 122 (Treatment), 147 (Control)
Test for heterogeneity chi-square=5.05 df=2 p=0.08 I² =60.4%
Test for overall effect z=7.17 p<0.00001
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